Global Hepatocellular Carcinoma Targeted Drug Supply, Demand and Key Producers, 2023-2029

Page: 108

Published Date: 03 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global Hepatocellular Carcinoma Targeted Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The most effective targeted drug introduced for HCC has been sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).

This report studies the global Hepatocellular Carcinoma Targeted Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Hepatocellular Carcinoma Targeted Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Hepatocellular Carcinoma Targeted Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Hepatocellular Carcinoma Targeted Drug total market, 2018-2029, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Hepatocellular Carcinoma Targeted Drug total market, key domestic companies and share, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug revenue by player and market share 2018-2023, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by Type, CAGR, 2018-2029, (USD Million)
Global Hepatocellular Carcinoma Targeted Drug total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Hepatocellular Carcinoma Targeted Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma and CSPC, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Hepatocellular Carcinoma Targeted Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Hepatocellular Carcinoma Targeted Drug Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Hepatocellular Carcinoma Targeted Drug Market, Segmentation by Type
    Sorafenib
    Lenvatinib
    Regorafenib
    Other

Global Hepatocellular Carcinoma Targeted Drug Market, Segmentation by Application
    Hospital
    Retail Pharmacy
    Other

Companies Profiled:
    Bayer
    Eisai
    Zelgen
    Cipla
    Natco Pharma
    BEACON Pharma
    Jiangxi Shanxiang
    Yao Pharma
    CSPC
    CHIATAI Tianqing
    Simcere

Key Questions Answered
1. How big is the global Hepatocellular Carcinoma Targeted Drug market?
2. What is the demand of the global Hepatocellular Carcinoma Targeted Drug market?
3. What is the year over year growth of the global Hepatocellular Carcinoma Targeted Drug market?
4. What is the total value of the global Hepatocellular Carcinoma Targeted Drug market?
5. Who are the major players in the global Hepatocellular Carcinoma Targeted Drug market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Hepatocellular Carcinoma Targeted Drug Introduction
    1.2 World Hepatocellular Carcinoma Targeted Drug Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Hepatocellular Carcinoma Targeted Drug Total Market by Region (by Headquarter Location)
        1.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029)
        1.3.3 China Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029)
        1.3.4 Europe Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029)
        1.3.5 Japan Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029)
        1.3.6 South Korea Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029)
        1.3.7 ASEAN Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029)
        1.3.8 India Hepatocellular Carcinoma Targeted Drug Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Hepatocellular Carcinoma Targeted Drug Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Hepatocellular Carcinoma Targeted Drug Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)
    2.2 World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region
        2.2.1 World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region (2018-2023)
        2.2.2 World Hepatocellular Carcinoma Targeted Drug Consumption Value Forecast by Region (2024-2029)
    2.3 United States Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)
    2.4 China Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)
    2.5 Europe Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)
    2.6 Japan Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)
    2.7 South Korea Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)
    2.8 ASEAN Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)
    2.9 India Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029)

3 World Hepatocellular Carcinoma Targeted Drug Companies Competitive Analysis
    3.1 World Hepatocellular Carcinoma Targeted Drug Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Hepatocellular Carcinoma Targeted Drug Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Hepatocellular Carcinoma Targeted Drug in 2022
        3.2.3 Global Concentration Ratios (CR8) for Hepatocellular Carcinoma Targeted Drug in 2022
    3.3 Hepatocellular Carcinoma Targeted Drug Company Evaluation Quadrant
    3.4 Hepatocellular Carcinoma Targeted Drug Market: Overall Company Footprint Analysis
        3.4.1 Hepatocellular Carcinoma Targeted Drug Market: Region Footprint
        3.4.2 Hepatocellular Carcinoma Targeted Drug Market: Company Product Type Footprint
        3.4.3 Hepatocellular Carcinoma Targeted Drug Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison
        4.2.1 United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Hepatocellular Carcinoma Targeted Drug Companies and Market Share, 2018-2023
        4.3.1 United States Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2018-2023)
    4.4 China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue and Market Share, 2018-2023
        4.4.1 China Based Hepatocellular Carcinoma Targeted Drug Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2018-2023)
    4.5 Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Hepatocellular Carcinoma Targeted Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Sorafenib
        5.2.2 Lenvatinib
        5.2.3 Regorafenib
        5.2.4 Other
    5.3 Market Segment by Type
        5.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2018-2023)
        5.3.2 World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2024-2029)
        5.3.3 World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Hepatocellular Carcinoma Targeted Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Retail Pharmacy
        6.2.3 Other
    6.3 Market Segment by Application
        6.3.1 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2018-2023)
        6.3.2 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2024-2029)
        6.3.3 World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Bayer
        7.1.1 Bayer Details
        7.1.2 Bayer Major Business
        7.1.3 Bayer Hepatocellular Carcinoma Targeted Drug Product and Services
        7.1.4 Bayer Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Bayer Recent Developments/Updates
        7.1.6 Bayer Competitive Strengths & Weaknesses
    7.2 Eisai
        7.2.1 Eisai Details
        7.2.2 Eisai Major Business
        7.2.3 Eisai Hepatocellular Carcinoma Targeted Drug Product and Services
        7.2.4 Eisai Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Eisai Recent Developments/Updates
        7.2.6 Eisai Competitive Strengths & Weaknesses
    7.3 Zelgen
        7.3.1 Zelgen Details
        7.3.2 Zelgen Major Business
        7.3.3 Zelgen Hepatocellular Carcinoma Targeted Drug Product and Services
        7.3.4 Zelgen Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Zelgen Recent Developments/Updates
        7.3.6 Zelgen Competitive Strengths & Weaknesses
    7.4 Cipla
        7.4.1 Cipla Details
        7.4.2 Cipla Major Business
        7.4.3 Cipla Hepatocellular Carcinoma Targeted Drug Product and Services
        7.4.4 Cipla Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Cipla Recent Developments/Updates
        7.4.6 Cipla Competitive Strengths & Weaknesses
    7.5 Natco Pharma
        7.5.1 Natco Pharma Details
        7.5.2 Natco Pharma Major Business
        7.5.3 Natco Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
        7.5.4 Natco Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Natco Pharma Recent Developments/Updates
        7.5.6 Natco Pharma Competitive Strengths & Weaknesses
    7.6 BEACON Pharma
        7.6.1 BEACON Pharma Details
        7.6.2 BEACON Pharma Major Business
        7.6.3 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
        7.6.4 BEACON Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 BEACON Pharma Recent Developments/Updates
        7.6.6 BEACON Pharma Competitive Strengths & Weaknesses
    7.7 Jiangxi Shanxiang
        7.7.1 Jiangxi Shanxiang Details
        7.7.2 Jiangxi Shanxiang Major Business
        7.7.3 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product and Services
        7.7.4 Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Jiangxi Shanxiang Recent Developments/Updates
        7.7.6 Jiangxi Shanxiang Competitive Strengths & Weaknesses
    7.8 Yao Pharma
        7.8.1 Yao Pharma Details
        7.8.2 Yao Pharma Major Business
        7.8.3 Yao Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
        7.8.4 Yao Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Yao Pharma Recent Developments/Updates
        7.8.6 Yao Pharma Competitive Strengths & Weaknesses
    7.9 CSPC
        7.9.1 CSPC Details
        7.9.2 CSPC Major Business
        7.9.3 CSPC Hepatocellular Carcinoma Targeted Drug Product and Services
        7.9.4 CSPC Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 CSPC Recent Developments/Updates
        7.9.6 CSPC Competitive Strengths & Weaknesses
    7.10 CHIATAI Tianqing
        7.10.1 CHIATAI Tianqing Details
        7.10.2 CHIATAI Tianqing Major Business
        7.10.3 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product and Services
        7.10.4 CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 CHIATAI Tianqing Recent Developments/Updates
        7.10.6 CHIATAI Tianqing Competitive Strengths & Weaknesses
    7.11 Simcere
        7.11.1 Simcere Details
        7.11.2 Simcere Major Business
        7.11.3 Simcere Hepatocellular Carcinoma Targeted Drug Product and Services
        7.11.4 Simcere Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Simcere Recent Developments/Updates
        7.11.6 Simcere Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Hepatocellular Carcinoma Targeted Drug Industry Chain
    8.2 Hepatocellular Carcinoma Targeted Drug Upstream Analysis
    8.3 Hepatocellular Carcinoma Targeted Drug Midstream Analysis
    8.4 Hepatocellular Carcinoma Targeted Drug Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Hepatocellular Carcinoma Targeted Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Hepatocellular Carcinoma Targeted Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Hepatocellular Carcinoma Targeted Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Hepatocellular Carcinoma Targeted Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Hepatocellular Carcinoma Targeted Drug Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Hepatocellular Carcinoma Targeted Drug Players in 2022
    Table 12. World Hepatocellular Carcinoma Targeted Drug Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Hepatocellular Carcinoma Targeted Drug Company Evaluation Quadrant
    Table 14. Head Office of Key Hepatocellular Carcinoma Targeted Drug Player
    Table 15. Hepatocellular Carcinoma Targeted Drug Market: Company Product Type Footprint
    Table 16. Hepatocellular Carcinoma Targeted Drug Market: Company Product Application Footprint
    Table 17. Hepatocellular Carcinoma Targeted Drug Mergers & Acquisitions Activity
    Table 18. United States VS China Hepatocellular Carcinoma Targeted Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Hepatocellular Carcinoma Targeted Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2018-2023)
    Table 23. China Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Hepatocellular Carcinoma Targeted Drug Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Hepatocellular Carcinoma Targeted Drug Revenue Market Share (2018-2023)
    Table 29. World Hepatocellular Carcinoma Targeted Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Hepatocellular Carcinoma Targeted Drug Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Hepatocellular Carcinoma Targeted Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Hepatocellular Carcinoma Targeted Drug Market Size by Application (2024-2029) & (USD Million)
    Table 35. Bayer Basic Information, Area Served and Competitors
    Table 36. Bayer Major Business
    Table 37. Bayer Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 38. Bayer Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Bayer Recent Developments/Updates
    Table 40. Bayer Competitive Strengths & Weaknesses
    Table 41. Eisai Basic Information, Area Served and Competitors
    Table 42. Eisai Major Business
    Table 43. Eisai Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 44. Eisai Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Eisai Recent Developments/Updates
    Table 46. Eisai Competitive Strengths & Weaknesses
    Table 47. Zelgen Basic Information, Area Served and Competitors
    Table 48. Zelgen Major Business
    Table 49. Zelgen Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 50. Zelgen Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Zelgen Recent Developments/Updates
    Table 52. Zelgen Competitive Strengths & Weaknesses
    Table 53. Cipla Basic Information, Area Served and Competitors
    Table 54. Cipla Major Business
    Table 55. Cipla Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 56. Cipla Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Cipla Recent Developments/Updates
    Table 58. Cipla Competitive Strengths & Weaknesses
    Table 59. Natco Pharma Basic Information, Area Served and Competitors
    Table 60. Natco Pharma Major Business
    Table 61. Natco Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 62. Natco Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Natco Pharma Recent Developments/Updates
    Table 64. Natco Pharma Competitive Strengths & Weaknesses
    Table 65. BEACON Pharma Basic Information, Area Served and Competitors
    Table 66. BEACON Pharma Major Business
    Table 67. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 68. BEACON Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. BEACON Pharma Recent Developments/Updates
    Table 70. BEACON Pharma Competitive Strengths & Weaknesses
    Table 71. Jiangxi Shanxiang Basic Information, Area Served and Competitors
    Table 72. Jiangxi Shanxiang Major Business
    Table 73. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 74. Jiangxi Shanxiang Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Jiangxi Shanxiang Recent Developments/Updates
    Table 76. Jiangxi Shanxiang Competitive Strengths & Weaknesses
    Table 77. Yao Pharma Basic Information, Area Served and Competitors
    Table 78. Yao Pharma Major Business
    Table 79. Yao Pharma Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 80. Yao Pharma Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Yao Pharma Recent Developments/Updates
    Table 82. Yao Pharma Competitive Strengths & Weaknesses
    Table 83. CSPC Basic Information, Area Served and Competitors
    Table 84. CSPC Major Business
    Table 85. CSPC Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 86. CSPC Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. CSPC Recent Developments/Updates
    Table 88. CSPC Competitive Strengths & Weaknesses
    Table 89. CHIATAI Tianqing Basic Information, Area Served and Competitors
    Table 90. CHIATAI Tianqing Major Business
    Table 91. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 92. CHIATAI Tianqing Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. CHIATAI Tianqing Recent Developments/Updates
    Table 94. Simcere Basic Information, Area Served and Competitors
    Table 95. Simcere Major Business
    Table 96. Simcere Hepatocellular Carcinoma Targeted Drug Product and Services
    Table 97. Simcere Hepatocellular Carcinoma Targeted Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 98. Global Key Players of Hepatocellular Carcinoma Targeted Drug Upstream (Raw Materials)
    Table 99. Hepatocellular Carcinoma Targeted Drug Typical Customers
List of Figure
    Figure 1. Hepatocellular Carcinoma Targeted Drug Picture
    Figure 2. World Hepatocellular Carcinoma Targeted Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Hepatocellular Carcinoma Targeted Drug Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Hepatocellular Carcinoma Targeted Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Hepatocellular Carcinoma Targeted Drug Revenue (2018-2029) & (USD Million)
    Figure 13. Hepatocellular Carcinoma Targeted Drug Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Hepatocellular Carcinoma Targeted Drug Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Hepatocellular Carcinoma Targeted Drug by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Hepatocellular Carcinoma Targeted Drug Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Hepatocellular Carcinoma Targeted Drug Markets in 2022
    Figure 27. United States VS China: Hepatocellular Carcinoma Targeted Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Hepatocellular Carcinoma Targeted Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Hepatocellular Carcinoma Targeted Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type in 2022
    Figure 31. Sorafenib
    Figure 32. Lenvatinib
    Figure 33. Regorafenib
    Figure 34. Other
    Figure 35. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Type (2018-2029)
    Figure 36. World Hepatocellular Carcinoma Targeted Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 37. World Hepatocellular Carcinoma Targeted Drug Market Size Market Share by Application in 2022
    Figure 38. Hospital
    Figure 39. Retail Pharmacy
    Figure 40. Other
    Figure 41. Hepatocellular Carcinoma Targeted Drug Industrial Chain
    Figure 42. Methodology
    Figure 43. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Hepatocellular Carcinoma Targeted Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Hepatocellular Carcinoma Targeted Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 06 Feb 2023

date Pharma & Healthcare

The most effective targeted drug introduced for HCC has been sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).

Global Hepatocellular Carcinoma Targeted Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Hepatocellular Carcinoma Targeted Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 05 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Hepatocellular Carcinoma Targeted Drug market size was valued at USD 869.5 million in 2023 and is forecast to a readjusted size of USD 1439.2 million by 2030 with a CAGR of 7.5% during review period.

Global Hepatocellular Carcinoma Targeted Drug Supply, Demand and Key Producers, 2024-2030

Global Hepatocellular Carcinoma Targeted Drug Supply, Demand and Key Producers, 2024-2030

date 24 Feb 2024

date Pharma & Healthcare

The global Hepatocellular Carcinoma Targeted Drug market size is expected to reach $ 1439.2 million by 2030, rising at a market growth of 7.5% CAGR during the forecast period (2024-2030).

Global Hepatocellular Carcinoma Targeted Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Global Hepatocellular Carcinoma Targeted Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031

date 13 Jan 2025

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Hepatocellular Carcinoma Targeted Drug market size was valued at US$ 1005 million in 2024 and is forecast to a readjusted size of USD 1671 million by 2031 with a CAGR of 7.6% during review period.

Product Tags

Hepatocellular Carcinoma Targeted Drug

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>